Log In Sign up
The largest database of trusted experimental protocols

Nmri nude mice

Manufactured by Janvier Labs
Visit Supplier
Sourced in France

NMRI nude mice are genetically modified mice that lack a functional immune system, specifically the thymus. This allows for the study of human tumor xenografts and other human disease models without rejection by the host immune system.

Automatically generated - may contain errors

Lab products found in correlation

Matrigel, by BD (3 mentions) U87mg, by American Type Culture Collection (2 mentions) Ivis kinetic, by PerkinElmer (2 mentions) D luciferin, by Promega (2 mentions) Dimethyl sulfoxide (dmso), by Merck Group (2 mentions) Phosphate buffered saline (pbs), by Thermo Fisher Scientific (1 mentions) Vivact 40, by Scanco (1 mentions) Infusion syringe pump, by Harvard Apparatus (1 mentions) Matrigel, by Corning (1 mentions) Phosphate buffered saline (pbs), by Corning (1 mentions) Sucrose, by Merck Group (1 mentions) Orcaii bt 512g, by Hamamatsu Photonics (1 mentions) Wasabi software, by Hamamatsu Photonics (1 mentions) X rad 320, by Precision X-Ray (1 mentions) Accutom 50, by Struers (1 mentions) H1703, by American Type Culture Collection (1 mentions) Hcc827, by American Type Culture Collection (1 mentions) H1993, by American Type Culture Collection (1 mentions) Penicillin streptomycin, by Thermo Fisher Scientific (1 mentions) Scn400, by Leica (1 mentions)

Spelling variants of this product

NMRI mice (30 citations) Nude mice (3 citations) NMRI nude female mice (3 citations) Rj:NMRI-nude mice (2 citations)

41 protocols using nmri nude mice

1

NIR Fluorescence Imaging of Tumor Targeting

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animal experiments were performed in accordance with the Institutional Animal Care and Use Committee at Grenoble Alpes University. These experiments were also approved by the Animal Ethics Committee of the French Ministry, under the agreement number APAFIS #8782. The experiments were performed at the Optimal (Small Animal Imaging Platform) platform, IAB Grenoble.
U-87 MG cancer cells (5 million cells per 100 µL PBS) were injected subcutaneously on the right flank of female NMRI nude mice (6-8-week-old) (Janvier Labs, Le Genest-Saint Isle, France). After tumor growth (~two weeks), 6 mice were anesthetized (air/isoflurane 4% for induction and 2% thereafter) and injected intravenously in the tail vein with 200 µL of aza-SWIR-BSH-01 (600 µM in PBS). Whole-body NIR fluorescence images were acquired before and 2, 5, 24, and 48 h post-administration. Three mice were euthanized at 24 and 48 h, respectively, and their organs were sampled for ex vivo fluorescence imaging. Acquired images were analyzed using ImageJ software. Semi-quantitative data were obtained by drawing regions of interest (ROI) around the organs. The fluorescence imaging was performed using a Pear Trilogy LI-COR system with a laser excitation source of 785 nm and a CCD (charge couple device) collecting fluorescence > 820 nm.
Kalot G., Godard A., Busser B., Pliquett J., Broekgaarden M., Motto-Ros V., Wegner K.D., Resch-Genger U., Köster U., Denat F., Coll J.L., Bodio E., Goze C, & Sancey L. (2020). Aza-BODIPY: A New Vector for Enhanced Theranostic Boron Neutron Capture Therapy Applications. Cells, 9(9), 1953.
+ Open protocol
+ Expand
2

Xenograft Mouse Model For Research

Check if the same lab product or an alternative is used in the 5 most similar protocols
NMRI nude mice were purchased from Janvier (Le Genest-Saint-Isle, France). For experiments, 6- to 10-week-old animals were used. C57BL/6J-Tyrc-2J mice were provided by the Translational Animal Research Center (TARC) of the Johannes Gutenberg University Mainz, Germany. All the mice were housed under specifically pathogen free (SPF) conditions at the TARC at a twelve-hour dark/light cycle with free access to food and water.
Animal experiments were approved by the ethics committee of the Landesuntersuchungsamt Rheinland-Pfalz and conducted according to the German Animal Protection Law §8 Abs. 1 TierSchG.
Stankovic N.D., Hoppmann N., Teodorczyk M., Kim E.L., Bros M., Giese A., Zipp F, & Schmidt M.H. (2016). No role of IFITM3 in brain tumor formation in vivo. Oncotarget, 7(52), 86388-86405.
+ Open protocol
+ Expand
3

Gefitinib and Vorinostat Combination in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
The effect of the combination of gefitinib and vorinostat was measured in established subcutaneous tumor-bearing mice. All the animal experiments were performed in agreement with the European Economic Community guidelines and the “Principles of Laboratory Animal Care” (NIH publication N 86-23 revised 1985). Animal experiment studies were approved through institutional guidelines and by the European Community for the use of experimental animals (authorization to experiment 2015031115126706). Female NMRI nude mice (6–8 weeks old, Janvier, Le Genest-Saint Isle, France) were injected subcutaneously in the flank with 20×106 H358 cells suspended in PBS or 5×106 PLC/PRF5 cells suspended in 50% Matrigel (BD Biosciences, San Jose, CA, USA). Tumor size was measured twice a week using a caliper, and the tumor volume was calculated as follows: length × (width)2 (link) ×0.4. When tumors of ~250 mm3 in size were detected, the mice were randomized into four groups (8–11 mice per group) and were orally treated with 5 (H358) or 50 mg/kg/day (PLC/PRF5) gefitinib and/or vorinostat (100 mg/kg/day) for either 5 (H358) or 3 (PLC/PRF5) days a week. Control mice received an oral vehicle (Tween/dimethyl sulfoxide). Mice bearing tumors ≥2 cm3 were euthanized immediately. At the end of the experiment, tumor samples were excised and frozen for Western blot and immunohistochemical analyses.
Jeannot V., Busser B., Vanwonterghem L., Michallet S., Ferroudj S., Cokol M., Coll J.L., Ozturk M, & Hurbin A. (2016). Synergistic activity of vorinostat combined with gefitinib but not with sorafenib in mutant KRAS human non-small cell lung cancers and hepatocarcinoma. OncoTargets and therapy, 9, 6843-6855.
+ Open protocol
+ Expand
4

Murine Osteosarcoma Xenograft Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
Four-week-old female Rj : NMRI-nude mice (Janvier, Le Genest Saint Isle, France) were housed under pathogen-free conditions at the Experimental Therapy Unit of Nantes University (France) in accordance with the institutional guidelines of the French Ethical Committee (CEEA Pays de la Loire no. 06: project authorization 8405). The mice were anesthetized by inhalation of isoflurane before receiving an intramuscular injection of 1.106 K-HOS parental or mutant cells near the tibia. For the in vivo experiments using SD-208 or verteporfin, at 5 days after the cell injections, groups of mice received 60 or 20 mg/kg SD-208 or the control vehicle twice a week by intraperitoneal injection. The mice were sacrificed when the tumor volume reached 1,000 mm3, and lung metastases were analyzed and counted in each group of mice.
Morice S., Danieau G., Tesfaye R., Mullard M., Brion R., Dupuy M., Ory B., Brounais-Le Royer B., Corre I., Redini F, & Verrecchia F. (2021). Involvement of the TGF-β Signaling Pathway in the Development of YAP-Driven Osteosarcoma Lung Metastasis. Frontiers in Oncology, 11, 765711.
+ Open protocol
+ Expand
5

Evaluating MTP-PlexA1 Impact on Tumor Growth

Check if the same lab product or an alternative is used in the 5 most similar protocols
Experiments were performed according to the Guide for Care and Use of Laboratory Animals (E67-6-482-21) and the European Directive with approval of the regional ethical committee (Reference AL/55/62/02/13). Heterotopic grafts were produced by injecting 106 cells in the flank of pathogen-free NMRI nude mice (Janvier, Le Genest Saint Isle, France). Intraperitoneal administration of vehicle (LDS 72 μM) or MTP-PlexA1 treatment (10–7 M) were done every days during 20 days when the tumors reached a minimal volume of 100 mm3. For the experiment conducted with cancer stem cell line NCH644mCherry, we performed bilateral grafting of 106 cells on each flank of 20 nude mice without treatment or pre-incubated for 1 hour with MTP-PlexA1 at 10–7 M. After 5 days, the fluorescence emission of developing tumors was recorded using the NightOwl system (Berthold) using appropriate excitation and emission filters (580 nm/620 nm respectively).
Jacob L., Sawma P., Garnier N., Meyer L.A., Fritz J., Hussenet T., Spenlé C., Goetz J., Vermot J., Fernandez A., Baumlin N., Aci-Sèche S., Orend G., Roussel G., Crémel G., Genest M., Hubert P, & Bagnard D. (2016). Inhibition of PlexA1-mediated brain tumor growth and tumor-associated angiogenesis using a transmembrane domain targeting peptide. Oncotarget, 7(36), 57851-57865.
+ Open protocol
+ Expand
6

Subcutaneous Xenograft Model of U87MG Glioblastoma in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Five weeks old female NMRI nude mice were purchased from Janvier (Le Genest-Saint-Isle, France) and housed in groups to acclimatize for a week upon arrival with light/dark period of 12/12 h and under controlled environmental conditions (temperature: 20–22 °C, relative humidity: 55%). Access to fresh water and standard pellet diet was provided ad libitum. Human glioblastoma cancer cell line U87MG (ATCC, Manassas, USA) was cultured in Dulbecco’s modified eagle medium (DMEM) supplemented with 10% fetal bovine serum and 1% penicillin–streptomycin at 37 °C and 5% CO2. Cells were harvested by trypsinization at a confluence of 70–90%. Mice were anesthetized (3–4% sevoflurane in 65% N2 and 35% O2) and ~ 4 × 106 U87MG cells resuspended in 100 μL PBS were injected subcutaneously into the right flank. Tumors were allowed to grow for 20 days. Tumor sizes were monitored using caliper measurements (Volume = 0.5 x (Length x Width2)).
Leth J.M., Newcombe E.A., Grønnemose A.L., Jørgensen J.T., Qvist K., Clausen A.S., Knudsen L.B., Kjaer A., Kragelund B.B., Jørgensen T.J, & Ploug M. (2023). Targeted imaging of uPAR expression in vivo with cyclic AE105 variants. Scientific Reports, 13, 17248.
+ Open protocol
+ Expand
7

In vivo Prostate Cancer Xenograft Study

Check if the same lab product or an alternative is used in the 5 most similar protocols
All mouse experiments were performed according to guidelines on animal care and with appropriate institutional certification of ethical comity and conducted in compliance with European Community. LNCaP (2 × 106 in 50% Matrigel) or PC3 (2 × 106) cells were injected subcutaneously into the right flank of 5-week-old male NMRI nude mice (Janvier, Le Genest-Saint-Isle, France). In the Enzastaurin/castration combination experiment, mice bearing LNCaP tumours of about 200–300 mm3 were separated randomly into several groups. Mice were then castrated by bilateral orchiectomy and treated one day after castration with 100 mg/kg Enzastaurin or vehicle by oral gavage every day. In the Enzastaurin/docetaxel combination experiment, mice bearing PC3 tumours of about 50–80 mm3 were separated randomly into several groups and treated with 100 mg/kg Enzastaurin or vehicle by oral gavage every day and/or with 5 mg/kg docetaxel at or PBS vehicle by intraperitoneal injection once a week. Tumour size was measured two times per week with a caliper and tumour volume was calculated with the formula: V = 4/3π*R12*R2 whereby radius 1 (R1), radius 2 (R2). Then, the percentage of tumour size was assigned to 100% at the beginning and each measure represents the percentage of tumour growth evolution.
Blanc C., Moktefi A., Jolly A., de la Grange P., Gay D., Nicolaiew N., Semprez F., Maillé P., Soyeux P., Firlej V., Vacherot F., Destouches D., Amiche M., Terry S., de la Taille A., Londoño-Vallejo A., Allory Y., Delbé J, & Hamma-Kourbali Y. (2022). The Neuropilin-1/PKC axis promotes neuroendocrine differentiation and drug resistance of prostate cancer. British Journal of Cancer, 128(5), 918-927.
+ Open protocol
+ Expand
8

Subcutaneous Tumor Xenograft Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
All animals were treated according to the guidelines approved by the Ethics and Animal Welfare Committee of Claude Bernard Lyon 1 University (protocol numbers DR2015-30 and DR2017-50). After incubation for 10 days, HEMC-SS spheroids were harvested, rinsed and temporarily placed in PBS (Gibco) for transplantation. Six-week-old female NMRI nude mice (Janvier Labs, Saint Berthevin, France) were injected subcutaneously in the right flank with a suspension containing 30 HEMC-SS spheroids in 50 μL PBS and 50 μL of MatrigelTM (approximately 300000 cells in total). Body weight was monitored three times per week for each mouse as well as tumor growth. After eight weeks, tumors reached a size between 50 and 100 mm3.
Aloy M.T., Sidi Boumedine J., Deville A., Kryza D., Gauthier A., Brichart-Vernos D., Ollier G., La Padula V., Lux F., Tillement O., Rodriguez-Lafrasse C, & Janier M. (2022). Proof of Concept of the Radiosensitizing Effect of Gadolinium Oxide Nanoparticles in Cell Spheroids and a Tumor-Implanted Murine Model of Chondrosarcoma. International Journal of Nanomedicine, 17, 6655-6673.
+ Open protocol
+ Expand
9

Subcutaneous Bone Formation in Mice

Check if the same lab product or an alternative is used in the 5 most similar protocols
Two female NMRI nude mice (5 weeks old) weighing 24 ± 0.5 g were purchased from Janvier (Le Genest St Isle, France). Facility rooms were maintained at constant temperature and humidity (25°C, 30-50 % relative humidity) and 12 h light/dark cycle. All animal studies were conducted in accordance with European Union guidelines and approved by the regional ethics committee. 4 FS membranes crosslinked at EDC10 and EDC50 and loaded at two different BMP-2 amounts (60 and 100 μg/mL) (as described in 2.6) were used for the preliminary tests. The dry membranes were implanted subcutaneously on the back of anesthetized mice. Anesthesia was performed using 4% Isoflurane 1.5 L/m air (Axience, Pantin, France) during induction and then 2% Isoflurane for maintenance with 1 L/m air. After implantation, suture stitches were performed. Subcutaneous membrane-mediated bone formation was monitored at days 0, 9, 21, 32,42 and 52 post-implantation by whole body scanner using microCT (Viva-CT 40; Scanco Medical, Brütisselen, Switzerland) with low Resolution settings (80 μm isotropic voxel size, voltage of 70 kV and a current of 114 mA). Quantification of bone formation was obtained using a low threshold of 150 mgHA/ccm. The region of interest was drawn around the observed new bone formations.
Caridade S.G., Monge C., Almodóvar J., Guillot R., Lavaud J., Josserand V., Coll J.L., Mano J.F, & Picart C. (2015). Myo-conductive and osteo-inductive free-standing polysaccharide membranes. Acta biomaterialia, 15, 139-149.
+ Open protocol
+ Expand
10

Orthotopic Glioblastoma Xenograft Model

Check if the same lab product or an alternative is used in the 5 most similar protocols
All experiments were performed in accordance with the European Directive 2010/63/EU and following the Belgian national regulation guidelines, and were approved by the ethical committee for animal care by the Faculty of Medicine of the Université Catholique de Louvain (2019/UCL/MD/004). Water and food were given ad libitum. Animal body weight was constantly monitored throughout the experiment.
Six-week-old female NMRI nude mice (Janvier, France) were anesthetized via intraperitoneal injection of ketamine/xylazine (100 and 13 mg/kg, respectively) and fixed on a stereotaxic frame. In 2 µL of native EMEM (ATCC), 4 × 104 cells of U-87MG (ATCC) were injected into the right frontal lobe using an infusion syringe pump (Harvard Apparatus, Holliston, MA, USA) mounted with a Hamilton syringe (26S gauge needle). The injection coordinates were 2.1 mm lateral and 0.5 mm posterior from the bregma, and 2.6 mm deep from the outer border of the cranium [12 (link)]. The tumor size monitoring was performed via MRI (see Section 2.3).
Conq J., Joudiou N., Ucakar B., Vanvarenberg K., Préat V, & Gallez B. (2023). Assessment of Hyperosmolar Blood–Brain Barrier Opening in Glioblastoma via Histology with Evans Blue and DCE-MRI. Biomedicines, 11(7), 1957.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!